BACKGROUND: Primary Ewing sarcoma (ES) can sometimes present as a chest-wall tumor. Multidisciplinary management, including chemotherapy and local treatment consisting of surgery, radiotherapy (RT), or both, has improved the survival of patients with localized ES; however, the best approach to achieving local control remains controversial. METHODS: We retrospectively analyzed data from 198 patients with non-metastatic ES of the chest wall, who were registered in the database of the German Society of Pediatric Hematology and Oncology between July 1998 and April 2009. The majority of patients (n = 130) presented with rib tumors; 7 patients received RT only, 85 patients underwent surgery alone, and 106 patients were treated with acombination of surgery and RT. RESULTS:Overall survival in all patients was 78 and 71 % at 3 and 5 years, respectively. Event-free survival at 5 years (5-year EFS) was 57 % in the RT group, 73 % in the surgery group and 63 % in the surgery + RT group. In patients with complete resections, 5-year EFS did not improve with the addition of RT compared with surgery alone. There was no difference in the 5-year EFS in patients with partial (63 %) or total (64 %) resection of the affected ribs, and median follow-up was 4.71 years (range 0.40-13.48). CONCLUSIONS: Complete tumor resection is the best way to achieve local control of ES of the chest wall; additional RT is only useful in patients with incomplete resection. The main limitation of this study was its retrospective nature, and the benefit of total resection of the affected ribs could not be proved.
RCT Entities:
BACKGROUND:Primary Ewing sarcoma (ES) can sometimes present as a chest-wall tumor. Multidisciplinary management, including chemotherapy and local treatment consisting of surgery, radiotherapy (RT), or both, has improved the survival of patients with localized ES; however, the best approach to achieving local control remains controversial. METHODS: We retrospectively analyzed data from 198 patients with non-metastatic ES of the chest wall, who were registered in the database of the German Society of Pediatric Hematology and Oncology between July 1998 and April 2009. The majority of patients (n = 130) presented with rib tumors; 7 patients received RT only, 85 patients underwent surgery alone, and 106 patients were treated with a combination of surgery and RT. RESULTS: Overall survival in all patients was 78 and 71 % at 3 and 5 years, respectively. Event-free survival at 5 years (5-year EFS) was 57 % in the RT group, 73 % in the surgery group and 63 % in the surgery + RT group. In patients with complete resections, 5-year EFS did not improve with the addition of RT compared with surgery alone. There was no difference in the 5-year EFS in patients with partial (63 %) or total (64 %) resection of the affected ribs, and median follow-up was 4.71 years (range 0.40-13.48). CONCLUSIONS: Complete tumor resection is the best way to achieve local control of ES of the chest wall; additional RT is only useful in patients with incomplete resection. The main limitation of this study was its retrospective nature, and the benefit of total resection of the affected ribs could not be proved.
Authors: Courtney J Harris; Irene Helenowski; Andrew J Murphy; Sara A Mansfield; Michael P LaQuaglia; Todd E Heaton; Michele Cavalli; Joseph T Murphy; Erika Newman; Richard E Overmen; Tanvi T Kartal; Jo Cooke-Barber; Addison Donaher; Marcus M Malek; Ranjeet Kalsi; Eugene S Kim; Michael J Zobel; Catherine J Goodhue; Bindi J Naik-Mathuria; Imory N Jefferson; Jonathan P Roach; Claudia Mata; Nelson Piché; Shahrzad Joharifard; Serge Sultan; Scott S Short; Rebecka L Meyers; Josh Bleicher; Hau D Le; Kevin Janek; Andreana Bütter; Jacob Davidson; Jennifer H Aldrink; Holden W Richards; Elisabeth T Tracy; Sarah J Commander; Elizabeth A Fialkowski; Misty Troutt; Roshni Dasgupta; Timothy B Lautz Journal: Ann Surg Date: 2020-11-04 Impact factor: 12.969
Authors: Christophoros N Foroulis; Athanassios D Kleontas; George Tagarakis; Chryssoula Nana; Ioannis Alexiou; Vasilis Grosomanidis; Paschalis Tossios; Elena Papadaki; Ioannis Kioumis; Sofia Baka; Paul Zarogoulidis; Kyriakos Anastasiadis Journal: Onco Targets Ther Date: 2016-04-19 Impact factor: 4.147
Authors: Sarah E Bosma; Lizz van der Heijden; Luis Sierrasesúmaga; Hans J H M Merks; Lianne M Haveman; Michiel A J van de Sande; Mikel San-Julián Journal: Cancers (Basel) Date: 2022-03-12 Impact factor: 6.639